Clinical Research Directory

Inclusion Criteria: 1. Women ≥ 18 and ≤ 70 years of age with treatment-naïve breast cancer 2. Histopathologically confirmed early or locally advanced three-negative invasive breast cancer as defined by the ASCO/CAP guidelines while meeting the following conditions: HER2 negative: IHC 0/1 + or IHC2 + but ISH negative; ER and/or PR negative (not eligible for endocrine therapy): IHC nuclear staining ≤ 1% 3. Tumor stage: II-III: Primary tumor size: ≥ 2cm 4. ECOG score 0 \~ 1; 5. Centrally confirmed BRCA1 or BRCA2 germline mutation; 6. Eligible level of organ function Exclusion Criteria: 1. Patients with metastatic breast cancer or bilateral breast cancer or inflammatory breast cancer; 2. Participated in other drug trials or received any anti-tumor therapy within 4 weeks before enrollment, including endocrine therapy, immunotherapy, biological therapy or tumor embolization; 3. Previously received PARPi therapy; 4. History of another primary malignancy; 5. Confirmed history of heart failure or systolic dysfunction (LVEF \< 50%); high risk uncontrolled cardiac arrhythmias, such as atrial tachycardia; 6. Female patients who are pregnant or lactating; 7. History of allergy to drugs in this study；